Sat 24 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma | Novartis | Terminated | QAW039/Fevipiprant | 3 | CQAW039A2315 | KFMC |
| A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma | Novartis | Terminated | QAW039/Fevipiprant | 3 | CQAW039A2315 | KFMC |
| A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants | Novartis | Completed | Everolimus + reduced tacrolimus VS.Tacrolimus | 3 | CRAD001H2307 | KFSH & RC-R |
| “MERS-CoV Infection Treated with a Combination of Lopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-Blind Randomized Trial (MIRACLE Trial)” | KAIMRC | Completed | Kaletra | 3 | RC15/142/R | NGHA-R |
| "RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity" | Novartis | Completed | Ranibizumab | 3 | CRFB002H2301E1 | KFSH & RC-R |
| Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection | Janssen-Cilag International NV | Completed | TMC435 (simeprevir) | 3b | TMC435HPC3014 | KFSH & RC-R |
| An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction | Roche | Terminated | Trastuzumab SC | 3b | ML28851 | KKUH (Closed) |
| An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women | 3 | |||||
| A RANDOMIZED, PARTIALLY-BLIND, PLACEBO-CONTROLLED, PILOT, DOSE-RANGING STUDY TO ASSESS THE EFFECT OF GWP42003 ON LIVER FAT LEVELS IN SUBJECT WITH FATTY LIVER DISEASE | GW | Rejected | Cannabidiol | 2a | GWZMD1188 | KKUH |
| A Phase III, Multicenter, Randomized, Open-Lable Clinical Trial Comparing the Efficacy and Safety of MK-0431 A (the Fixed-Dose Combination of Sitagliptin and Metformin) to That of Liraglutide in Patients With Type 2 Diabetes Mellitus | MSD | Terminated | MK-0431A (Sitagliptin / Metformin) vs Liraglutide | 3 | MK-0431A-180-00 | KKUH |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.